Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts.
10.5125/jkaoms.2014.40.6.291
- Author:
Taek Kyun KWON
1
;
Jae Min SONG
;
In Ryoung KIM
;
Bong Soo PARK
;
Chul Hoon KIM
;
In Kyo CHEONG
;
Sang Hun SHIN
Author Information
1. Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University, Yangsan, Korea. ssh8080@pusan.ac.kr
- Publication Type:Original Article
- Keywords:
Bone morphogenetic protein-2;
Alendronate;
Osteoblasts;
Macrophage colony-stimulating factor;
RANK ligand
- MeSH:
Alendronate;
Bisphosphonate-Associated Osteonecrosis of the Jaw;
Bone Remodeling;
Cell Survival;
Cytokines;
Enzyme-Linked Immunosorbent Assay;
Gene Expression;
Humans;
Macrophage Colony-Stimulating Factor;
Osteoblasts*;
Osteoclasts;
Osteoprotegerin;
RANK Ligand;
Real-Time Polymerase Chain Reaction
- From:Journal of the Korean Association of Oral and Maxillofacial Surgeons
2014;40(6):291-296
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVES: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a side effect of bisphophonate therapy that has been reported in recent years. Osteoclastic inactivity by bisphosphonate is the known cause of BRONJ. Bone morphogenetic protein-2 (BMP-2) plays an important role in the development of bone. Recombinant human BMP-2 (rhBMP-2) is potentially useful as an activation factor for bone repair. We hypothesized that rhBMP-2 would enhance the osteoclast-osteoblast interaction related to bone remodeling. MATERIALS AND METHODS: Human fetal osteoblast cells (hFOB 1.19) were treated with 100 microM alendronate, and 100 ng/mL rhBMP-2 was added. Cells were incubated for a further 48 hours, and cell viability was measured using an MTT assay. Expression of the three cytokines from osteoblasts, receptor activator of nuclear factor-kappaB ligand (RANKL), osteoprotegerin (OPG), and macrophage colony-stimulating factor (M-CSF), were analyzed by real-time polymerase chain reaction and enzyme-linked immunosorbent assay. RESULTS: Cell viability was decreased to 82.75%+/-1.00% by alendronate and then increased to 110.43%+/-1.35% after treatment with rhBMP-2 (P<0.05, respectively). OPG, RANKL, and M-CSF expression were all decreased by alendronate treatment. RANKL and M-CSF expression were increased, but OPG was not significantly affected by rhBMP-2. CONCLUSION: rhBMP2 does not affect OPG gene expression in hFOB, but it may increase RANKL and M-CSF gene expression.
